

IN THE SPECIFICATION**SHOWING OF CHANGES****Example 13**

The amino acid sequence of the protein [encoded by] of SEQ ID NO: [1]15 was analyzed for peptide sequences which correspond to HLA binding motifs. This was done using the algorithm taught by Parker et al., J. Immunol. 142:163 (1994), incorporated by reference. In the Table which follows, the amino acid sequence, the HLA molecule to which it presumably binds, and the positions in SEQ ID NO: 1 are given. The resulting complexes should provoke a cytolytic T cell response. This could be determined by one skilled in the art following methods taught by, e.g., van der Bruggen, et al., J. Eur. J. Immunol. 24: 3038-3043 (1994), incorporated by reference.

REMARKS

This is submitted in response to the Quayle action, as well as the incomplete and inaccurate statements made in paper number 45.

The sequence listing has been amended to recite an amino acid sequence, at SEQ ID NO: 15. To the same end, the specification has been amended.

Also submitted are replacement declaration/power of attorney forms, and a "Consent to Change Inventorship," missing previously. These should address the issues in point 2.

Regarding the examiner interview summary, this is incomplete and inaccurate, for the following reasons.

Late in January, the examiner issued an advisory action, incorrectly rejecting claims. In early February, the examiner admitted this, in a telephone interview she has chosen NOT to make of record, and promised to "fix it."

Nothing further was heard from the examiner, who was contacted, several times. Again, these telephone interviews were not made of record by the examiner, but are summarized in applicants' February 21 letter: The examiner was called upon to address this. Please note the last two lines of page 2:


"The examiner's response should include a complete explanation of these inappropriate, or applicants will take the matter up with the appropriate officials in the Commissioner's office."

Applicants have studied the March 25 action carefully, and do not find any comments addressing this, as requested. As such, it will be presumed that applicants' statements are agreed with, and this matter will now be taken up with, inter alia, the office of Quality Review.

Allowance of this application is expected.

Respectfully submitted,

FULBRIGHT & JAWORSKI, L.L.P.




Norman D. Hanson, Esq.
Registration No. 30,946

666 Fifth Avenue
New York, New York 10103-3198

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: The Table on Page 26 of the specification discloses sequences which lack SEQ ID NO: tags. See attached Office Action.

Applicant Must Provide: ONLY IF THE CRF/PAPR COPY SEQUENCE LISTING DOES NOT CONTAIN SAID SEQUENCES.

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

RECEIVED

JUN 11 2003

TECH CENTER 1600/2900

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE